Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Publikationen des W. G. Kerckhoff-Instituts     Display Documents



ID: 474484.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Publikationen des W. G. Kerckhoff-Instituts
Long-term therapy with inhaled iloprost in patients with pulmonary hypertension
Authors:Olschewski, H.; Hoeper, M. M.; Behr, J.; Ewert, R.; Meyer, A.; Borst, M. M.; Winkler, J.; Pfeifer, M.; Wilkens, H.; Ghofrani, H. A.; Nikkho, S.; Seeger, W.
Date of Publication (YYYY-MM-DD):2010
Title of Journal:Respir Med
Audience:Not Specified
Abstract / Description:AIMS: To investigate the long-term safety of inhaled iloprost in patients with pulmonary hypertension (pH), including idiopathic PAH (IPAH group) and other forms of pulmonary hypertension (PHother). METHODS AND RESULTS: Sixty-three patients (IPAH group, n=40, PHother n=23) were enrolled to receive inhaled iloprost either from baseline or after 3 months in a prospective, open-label 2-year study. Iloprost was inhaled 6-9 times daily with a night pause employing a jet nebulizer delivering an inhaled single dose of 4mug at the mouthpiece. In the case of side effects the single dose was reduced to 2mug. Sixty patients received at least 1 dose of inhaled iloprost. Thirty-six patients completed at least 630 days of therapy (25 IPAH, 11 PHother), 19 patients dropped out prematurely and 8 patients died (3 IPAH, 5 PHother). There were no drug-induced toxicities and only mild to moderate side effects. The most common side effects were coughing and flushing. Two-year survival was estimated at 85% (IPAH group 91%, PHother 78%). A modified analysis was performed to correct for differential drop-out. It included follow-up data from the premature discontinuations and revealed a 2-year survival of 87% [95% CI, 76%-98%] in the IPAH group while the predicted survival was 63%. The iloprost dose increased by 16% over 2 years. CONCLUSION: Inhaled iloprost is well tolerated as long-term therapy and no substantial dose increase is required. Although uncontrolled, the data suggest a long-term clinical benefit from continued therapy with inhaled iloprost.
External Publication Status:published
Document Type:Article
Communicated by:N. N.
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:University Hospital Giessen and Marburg GmbH, Klinikstr 36, 35392 Giessen, Germany; Division of Pulmonology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 20, A-8036 Graz, Austria.
Identifiers:ISSN:1532-3064 (Electronic) 0954-6111 (Linking)
URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=..
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.